| scholarly article | Q13442814 |
| P2093 | author name string | Glaumann H | |
| Lindblad A | |||
| Strandvik B | |||
| P2860 | cites work | Excretion of bile acids in healthy children and children with cystic fibrosis | Q71492453 |
| Conjugation types of 7 beta-hydroxylated bile acids detected in healthy human urine | Q72645460 | ||
| The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial | Q72682269 | ||
| The major metabolites of ursodeoxycholic acid in human urine are conjugated with N-acetylglucosamine | Q72719820 | ||
| Determination of the hepatic galactose elimination capacity after a single intravenous injection in man: the reproducibility and the influence of uneven distribution | Q79691775 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up. | Q33623427 | ||
| Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis | Q34392767 | ||
| Prevalence of liver disease in cystic fibrosis | Q35626850 | ||
| Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis | Q39514969 | ||
| Liver disease and common-bile-duct stenosis in cystic fibrosis | Q39533300 | ||
| Bile acid profiles in urine of patients with liver diseases | Q39704285 | ||
| Pharmacology of ursodeoxycholic acid, an enterohepatic drug. | Q40571618 | ||
| Heterologous expression of delta F508 CFTR results in decreased sialylation of membrane glycoconjugates | Q41492766 | ||
| Reduced microbial transformation of bile acids in cystic fibrosis | Q41836509 | ||
| Abnormal urinary bile acids in a patient suffering from cerebrotendinous xanthomatosis during oral administration of ursodeoxycholic acid | Q42223427 | ||
| Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis | Q42280172 | ||
| Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis | Q43551362 | ||
| Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis | Q43814867 | ||
| Sclerosing cholangitis in cystic fibrosis | Q45333556 | ||
| Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study | Q46492520 | ||
| Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. | Q51604167 | ||
| Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. | Q54118475 | ||
| A simple method for determination of antipyrine clearance | Q61794939 | ||
| Hepatic changes in young infants with cystic fibrosis: Possible relation to focal biliary cirrhosis | Q66935580 | ||
| The fecal microflora and bile acids in children with cystic fibrosis | Q66969900 | ||
| Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease | Q68079285 | ||
| Immunomodulatory effects of ursodeoxycholic acid on immune responses | Q68225187 | ||
| Morphological findings in the liver of children with cystic fibrosis: a light and electron microscopical study | Q69887081 | ||
| Biotransformation of orally administered ursodeoxycholic acid in man as observed in gallbladder bile, serum and urine | Q70587771 | ||
| Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts | Q70638072 | ||
| Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy | Q70670255 | ||
| Efficacy of bile acid therapy for gallstone dissolution: a meta-analysis of randomized trials | Q70690065 | ||
| Urinary bile acid excretion in correlation to liver histopathology in cystic fibrosis | Q71170990 | ||
| Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis | Q71173367 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| P304 | page(s) | 166-174 | |
| P577 | publication date | 1998-01-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease | |
| P478 | volume | 27 |
| Q85564033 | A pilot study of the characterization of hepatic tissue strain in children with cystic-fibrosis-associated liver disease (CFLD) by acoustic radiation force impulse imaging |
| Q36036857 | Antifibrotic therapy in chronic liver disease |
| Q37887181 | Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease |
| Q46383706 | Bioequivalence of a new liquid formulation of ursodeoxycholic acid (Ursofalk suspension) and Ursofalk capsules measured by plasma pharmacokinetics and biliary enrichment |
| Q42515580 | Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells |
| Q37317654 | Current and future anti-fibrotic therapies for chronic liver disease |
| Q22306058 | Cystic Fibrosis Adult Care |
| Q44558476 | Cystic fibrosis liver disease: to transplant or not to transplant? |
| Q37801087 | Cystic fibrosis-associated liver disease |
| Q35514538 | Cystic fibrosis-related liver disease: a single-center experience |
| Q38252636 | Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations |
| Q73156200 | Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease |
| Q36396784 | Diagnostic approach to patients with cholestatic jaundice |
| Q28079538 | Digestive Enzyme Supplementation in Gastrointestinal Diseases |
| Q77545932 | Digestive and nutritional management |
| Q44927735 | Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis. |
| Q53627194 | Gastrointestinal Manifestations of Cystic Fibrosis. |
| Q35765194 | Hepatobiliary complications of cystic fibrosis |
| Q57651838 | Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy |
| Q24186697 | Interventions for managing advanced liver disease in cystic fibrosis |
| Q37850707 | Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal intestinal obstruction syndrome, and constipation |
| Q28141076 | Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management |
| Q91325739 | Liver Disease in Cystic Fibrosis: Illuminating the Black Box |
| Q79325382 | Liver involvement in cystic fibrosis |
| Q33784011 | Liver involvement in cystic fibrosis. |
| Q33839732 | Liver transplantation in patients with cystic fibrosis: analysis of United Network for Organ Sharing data |
| Q49078988 | Longitudinal Transient Elastography Measurements Used in Follow-up for Patients with Cystic Fibrosis |
| Q35032212 | Managing liver failure |
| Q35734498 | Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease |
| Q34017604 | Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets |
| Q35099096 | Metabolic liver disease in the young adult |
| Q73114499 | Natural history of liver disease in cystic fibrosis |
| Q78053154 | Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension |
| Q92532305 | Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases |
| Q32142338 | Primary cultures of human hepatocytes but not HepG2 hepatoblastoma cells are suitable for the study of glycosidic conjugation of bile acids. |
| Q33723536 | Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases |
| Q49334378 | Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease |
| Q45137237 | Role of ursodeoxycholic acid in pediatric cholestatic disease |
| Q53928769 | Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. |
| Q35272532 | Serum hyaluronic acid concentrations are increased in cystic fibrosis patients with liver disease. |
| Q92157055 | Structural and functional characterization of a novel acidophilic 7α-hydroxysteroid dehydrogenase |
| Q46884201 | The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid |
| Q34170449 | The cell and molecular biology of hepatic fibrogenesis. Clinical and therapeutic implications |
| Q36085123 | The gallbladder and biliary tract in cystic fibrosis |
| Q40564391 | Treatment of Gastrointestinal Problems in Cystic Fibrosis |
| Q34330984 | Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. |
| Q43815262 | Ursodeoxycholic acid action on the transport function of the small intestine in normal and cystic fibrosis mice |
| Q77598543 | Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications |
| Q47198958 | Ursodeoxycholic acid therapy in cystic fibrosis liver disease--a retrospective long-term follow-up case-control study |
| Q33866782 | Ursodeoxycholic acid treatment of vanishing bile duct syndromes |
| Q34515643 | Use of ursodeoxycholic acid in patients with liver disease |
| Q51186195 | [Cystic fibrosis associated with liver disease]. |
| Q82734840 | [Liver complications in cystic fibrosis. Specific questions in adults?] |
| Q79363164 | [Question 5. What management for hepatobiliary injury in the course of cystic fibrosis?] |
| Q79363162 | [Question 5. What management in hepatobiliary injury in the course of cystic fibrosis? Specific therapeutic strategy of hepatobiliary injury in the course of cystic fibrosis] |
Search more.